SLC22A11
ENSG00000168065
Target class
Transporter
Chromosome
11
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Other names
- OAT4
- Target name
- SLC22A11
- Gene name
- Solute carrier family 22 member 11
- Gene symbol
- SLC22A11
- Protein name
- Solute carrier family 22 member 11 (Organic anion transporter 4) (OAT4) (Organic anion:dicarboxylate exchanger OAT4)
- Gene biotype
- Protein coding
- Gene family
- Solute carrier family 22
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 2
- Highest tissue expression
- 28.42
- Tissue specificity (Gini)
- 0.942
- Tissue specificity (tau)
- 0.992
- KEGG gene identifiers
- hsa:55867
- Reactome pathways
- R-HSA-561048
- Protein interaction confidence
- 0.806636
- Protein interaction partners
- 11
- End position
- 64572875
- Start position
- 64555690
- Chromosome
- 11
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Apical cell membrane
- Multi-pass membrane protein . Basal cell membrane
- Multi-pass membrane protein . Note=Expressed at the apical membrane of the proximal tubule epithelial cells (PubMed:15037815). Expressed at the basal membrane of the syncytiotrophoblast (PubMed:12409283). .
- PubMed 15291761
- PubMed 15576633
- PubMed 15037815
- PubMed 12409283
- Tissue specificity (tau)
- 0.992246
- Expression inequality (Gini)
- 0.941646
Expression in transcripts per million
- Kidney - Cortex
- 28.42
- Kidney - Medulla
- 9.37
- Testis
- 0.28
- Spleen
- 0.15
- Cervix - Endocervix
- 0.14
Expression in transcripts per million
- Kidney - Cortex28.42
- Kidney - Medulla9.37
- Testis0.28
- Spleen0.15
- Cervix - Endocervix0.14
- Adrenal Gland0.13
- Liver0.12
- Ovary0.09
- Brain - Cerebellum0.09
- Uterus0.09
- Brain - Cerebellar Hemisphere0.09
- Thyroid0.07
- Pituitary0.06
- Cervix - Ectocervix0.06
- Prostate0.06
- Fallopian Tube0.05
- Pancreas0.05
- Brain - Substantia nigra0.04
- Breast - Mammary Tissue0.04
- Artery - Aorta0.04
- Nerve - Tibial0.04
- Brain - Spinal cord (cervical c-1)0.04
- Colon - Transverse0.03
- Small Intestine - Terminal Ileum0.03
- Minor Salivary Gland0.03
And 29 more, listed on the interactive page.
- GO:0015732
- GO:0046415
- GO:0055085
- GO:0005886
- GO:0009897
- GO:0009925
- GO:0016324
- GO:0070062
- GO:0005452
- GO:0005515
- GO:0015132
- GO:0015291
- GO:0022857
Related records
Trials (61)
- 10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
- A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)
- A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.
- A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults
- A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)
- A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood
- A Study of Baricitinib and Probenecid in Healthy Participants
- A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease
- A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants
- A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
- A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers
- A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects
- A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection
- A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients
- A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
- A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
- Addition of Probenecid to Penicillin-V Therapy
- An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS
- Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers
- AV-101 Alone and in Combination With Probenecid in Healthy Subjects
Drugs (1)
- Probenecid Solute carrier family 22 member 11 inhibitor